Does it really matter, when another company has a big head start? Being in Phase III already Genentech/BIIB may expand the market substantially before the (better) transgenic product comes to market.
So it will only mean a larger market to be attacked, isn't it?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.